NASDAQ:IBIO iBio Q1 2027 Earnings Date & Estimates $0.82 0.00 (-0.06%) As of 12:19 PM Eastern This is a fair market value price provided by Massive. Learn more. iBio is estimated to report Q1 2027 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for November 13, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ1 2027Announcement DateNovember 11, 2026TimeBefore Market OpensConference Call DateNovember 13, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from iBio in Q1 2027iBio is expected to post earnings of -$0.07 per share on revenue of $25 thousand. In the same quarter a year earlier iBio reported -$0.11 per share on revenue of $100 thousand. iBio last reported on August 28, 2026, posting -$0.04 per share and beating the -$0.0655 consensus estimate. iBio has beaten the consensus EPS estimate in 1 of its last 5 quarters.Consensus EstimatesConsensus EPS-$0.07Expected Revenue$25 thousandPrior-Year EPS-$0.11Prior-Year Revenue$100 thousandExpected Revenue Growth-75.0%Recent Track RecordLast ReportedQ4 2026Last Quarter EPS-$0.04 (Beat by +$0.0255)EPS Beat Rate1 of last 5 quartersPrepare for the Q1 2027 CallEarnings HistoryCompany ProfileQ4 2026 Earnings ReportQ3 2026 Earnings ReportQ2 2026 Earnings Report iBio Q1 2027 Earnings FAQ When does iBio report Q1 2027 earnings? iBio (NASDAQ:IBIO) is estimated to report Q1 2027 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is iBio's Q1 2027 earnings call? iBio's Q1 2027 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for iBio? Analysts expect iBio to post earnings of -$0.07 per share for Q1 2027. How much revenue is iBio expected to report? The consensus revenue estimate for iBio is $25 thousand for Q1 2027. iBio Earnings HeadlinesiBio to Participate in Upcoming Investor ConferencesNovember 2 at 4:30 PM | globenewswire.comAlpha buying: 3 beaten-down biotech stocks backed by a specialist investor - MSNOctober 29, 2026 | msn.comElon Warns "America Will Go Bankrupt". Trump's Plan Inside.The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Efficiency under President Trump - has gone on record saying the U.S. is '1,000% going to go bankrupt' if the trajectory doesn't change. The Trump administration preserved a little-known IRS loophole that allows everyday Americans to shield their retirement savings from the next wave of market turbulence. A free 2026 Wealth Protection Guide walks through the steps to use it.November 4 at 1:00 AM | American Hartford Gold (Ad)iBio, Inc. (IBIO) - What Are Investment Firms Thinking About This Stock?October 28, 2026 | americanbankingnews.comiBio Shareholders Approve Governance and Capital Structure ChangesOctober 19, 2026 | tipranks.comIBio, Inc. Highlights Preclinical Body-Composition Data From Its Obese Non-Human Primate Study Evaluating IBIO-610October 13, 2026 | marketscreener.comMSee More iBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email. Email Address About iBioiBio (NASDAQ:IBIO) (NASDAQ: IBIO) is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify and optimize antibody candidates for potential use in cancer and other serious diseases. iBio’s discovery capabilities are built around proprietary antibody-design and profiling technologies, including platforms intended to improve the speed and quality of therapeutic antibody development. The company has also pursued its own preclinical pipeline while evaluating potential partnerships and licensing opportunities for its drug candidates and discovery technologies. Historically, iBio was known for plant-based protein manufacturing and biologics development through its FastPharming technology, which was designed to produce proteins and antibodies using engineered plants. In more recent years, the company has shifted its emphasis toward artificial intelligence-enabled antibody discovery and therapeutic development. iBio is headquartered in the United States and serves the biopharmaceutical industry through its research, development and collaboration activities.View iBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainMarriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestTower Semiconductor's Earnings Are Soaring—So Why Is Its Stock Down More Than 50%? Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026)Becton, Dickinson and Company (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
